Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1977 Feb;40(2):162–167. doi: 10.1136/jnnp.40.2.162

Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.

A Galea-Debono, P Jenner, C D Marsden, J D Parkes, D Tarsy, J Walters
PMCID: PMC492632  PMID: 864480

Abstract

It has been suggested that the therapeutic response to levodopa in patients with Parkinson's disease may be related to changes in plasma growth hormone concentration. In order to examine this problem, we have determined plasma DOPA and growth hormone levels after a standard oral levodopa load in 32 patients with Parkinson's disease. Levodopa caused an increase in plasma growth hormone concentration in 30 subjects. The magnitude and timing of this growth hormone response was not related to the clinical response, the presence or absence of response swings, or the occurrence of dyskinesias. The growth hormone response to levodopa is normal in patients with Parkinson's disease and not altered by long-term levodopa treatment.

Full text

PDF
162

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J. 1969 Dec 27;101(13):59–68. [PMC free article] [PubMed] [Google Scholar]
  2. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Mendez J. S., Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976 Mar 11;294(11):567–572. doi: 10.1056/NEJM197603112941101. [DOI] [PubMed] [Google Scholar]
  4. Curzon G., Kantamaneni B. D., Trigwell J. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients. Clin Chim Acta. 1972 Mar;37:335–341. doi: 10.1016/0009-8981(72)90453-6. [DOI] [PubMed] [Google Scholar]
  5. Denys E. H., Hofmann W. W. An in vitro study of biomechanical changes produced by hypermetabolism and hypometabolism in skeletal muscle. Neurology. 1972 Jan;22(1):22–31. doi: 10.1212/wnl.22.1.22. [DOI] [PubMed] [Google Scholar]
  6. Eddy R. L., Jones A. L., Chakmakjian Z. H., Silverthorne M. C. Effect of levodopa (L-DOPA) on human hypophyseal tropic hormone release. J Clin Endocrinol Metab. 1971 Oct;33(4):709–712. doi: 10.1210/jcem-33-4-709. [DOI] [PubMed] [Google Scholar]
  7. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974 May;24(5):431–441. doi: 10.1212/wnl.24.5.431. [DOI] [PubMed] [Google Scholar]
  8. Kruse-Larsen C., Garde K. Postmenopausal bleeding: another side-effect of levodopa. Lancet. 1971 Apr 3;1(7701):707–708. doi: 10.1016/s0140-6736(71)92730-9. [DOI] [PubMed] [Google Scholar]
  9. Maany I., Frazer A., Mendels J. Apomorphine: effect on growth hormone. J Clin Endocrinol Metab. 1975 Jan;40(1):162–163. doi: 10.1210/jcem-40-1-162. [DOI] [PubMed] [Google Scholar]
  10. Malarkey W. B., Cyrus J., Paulson G. W. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. J Clin Endocrinol Metab. 1974 Aug;39(2):229–235. doi: 10.1210/jcem-39-2-229. [DOI] [PubMed] [Google Scholar]
  11. Marsden C. D., Barry P. E., Parkes J. D., Zilkha K. J. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10–14. doi: 10.1136/jnnp.36.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  13. Mena I., Cotzias G. C., Brown F. C., Papavasiliou P. S., Miller S. T. Defective release of growth hormone in parkinsonism improved by levodopa. N Engl J Med. 1973 Feb 8;288(6):320–321. doi: 10.1056/NEJM197302082880614. [DOI] [PubMed] [Google Scholar]
  14. Mena I., Cotzias G. C. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med. 1975 Jan 23;292(4):181–184. doi: 10.1056/NEJM197501232920404. [DOI] [PubMed] [Google Scholar]
  15. Muenter M. D., Tyce G. M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971 Apr;46(4):231–239. [PubMed] [Google Scholar]
  16. SCHALCH D. S., PARKER M. L. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. doi: 10.1038/2031141a0. [DOI] [PubMed] [Google Scholar]
  17. Sachar E. J., Mushrush G., Perlow M., Weitzman E. D., Sassin J. Growth hormone responses to L-dopa in depressed patients. Science. 1972 Dec 22;178(4067):1304–1305. doi: 10.1126/science.178.4067.1304. [DOI] [PubMed] [Google Scholar]
  18. Shoulson I., Glaubiger G. A., Chase T. N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975 Dec;25(12):1144–1148. doi: 10.1212/wnl.25.12.1144. [DOI] [PubMed] [Google Scholar]
  19. Sweet R. D., McDowell F. H. Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology. 1974 Oct;24(10):953–956. doi: 10.1212/wnl.24.10.953. [DOI] [PubMed] [Google Scholar]
  20. Tang L. C., Cotzias G. C. Modification of the actions of some neuroactive drugs by growth hormone. Arch Neurol. 1976 Feb;33(2):131–134. doi: 10.1001/archneur.1976.00500020059009. [DOI] [PubMed] [Google Scholar]
  21. Tolosa E. S., Martin W. E., Cohen H. P., Jacobson R. L. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology. 1975 Feb;25(2):177–183. doi: 10.1212/wnl.25.2.177. [DOI] [PubMed] [Google Scholar]
  22. von Werder K., van Loon G. R., Yatsu F., Forsham P. H. Corticosteroid and growth hormone secretion in patients treated with L-dopa. Klin Wochenschr. 1970 Dec 15;48(24):1454–1456. doi: 10.1007/BF01484684. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES